Rhumbline Advisers Acadia Pharmaceuticals Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 178,141 shares of ACAD stock, worth $3.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
178,141
Previous 186,500 4.48%
Holding current value
$3.04 Million
Previous $3.03 Million 9.54%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$15.14 - $19.14 $126,555 - $159,991
-8,359 Reduced 4.48%
178,141 $2.74 Million
Q2 2024

Aug 01, 2024
BUY
$14.62 - $18.42 $31,009 - $39,068
2,121 Added 1.15%
186,500 $3.03 Million
Q1 2024

May 09, 2024
BUY
$17.79 - $30.86 $19,480 - $33,791
1,095 Added 0.6%
184,379 $3.41 Million
Q4 2023

Feb 08, 2024
SELL
$20.78 - $31.77 $23,190 - $35,455
-1,116 Reduced 0.61%
183,284 $5.74 Million
Q3 2023

Nov 09, 2023
BUY
$20.84 - $33.47 $75,524 - $121,295
3,624 Added 2.0%
184,400 $3.84 Million
Q2 2023

Aug 08, 2023
BUY
$17.8 - $25.65 $124,190 - $178,960
6,977 Added 4.01%
180,776 $4.33 Million
Q1 2023

May 11, 2023
BUY
$16.32 - $20.92 $14,965 - $19,183
917 Added 0.53%
173,799 $3.27 Million
Q4 2022

Feb 14, 2023
BUY
$14.2 - $18.63 $75,572 - $99,148
5,322 Added 3.18%
172,882 $2.75 Million
Q3 2022

Nov 10, 2022
BUY
$14.11 - $18.27 $233,449 - $302,277
16,545 Added 10.96%
167,560 $2.74 Million
Q2 2022

Aug 11, 2022
BUY
$13.01 - $27.22 $228,598 - $478,282
17,571 Added 13.17%
151,015 $2.13 Million
Q1 2022

May 12, 2022
BUY
$20.94 - $27.5 $104,930 - $137,802
5,011 Added 3.9%
133,444 $3.23 Million
Q4 2021

Feb 10, 2022
SELL
$16.79 - $27.09 $29,214 - $47,136
-1,740 Reduced 1.34%
128,433 $3 Million
Q3 2021

Nov 12, 2021
BUY
$15.78 - $24.77 $26,052 - $40,895
1,651 Added 1.28%
130,173 $2.16 Million
Q2 2021

Aug 05, 2021
BUY
$19.4 - $27.42 $249,095 - $352,072
12,840 Added 11.1%
128,522 $3.14 Million
Q1 2021

May 06, 2021
SELL
$25.02 - $54.99 $228,032 - $501,178
-9,114 Reduced 7.3%
115,682 $2.99 Million
Q4 2020

Feb 10, 2021
BUY
$41.04 - $56.79 $4,104 - $5,679
100 Added 0.08%
124,796 $6.67 Million
Q3 2020

Nov 12, 2020
SELL
$36.42 - $57.0 $273,696 - $428,355
-7,515 Reduced 5.68%
124,696 $5.14 Million
Q2 2020

Aug 13, 2020
SELL
$39.26 - $52.73 $1.19 Million - $1.6 Million
-30,324 Reduced 18.66%
132,211 $6.41 Million
Q1 2020

May 06, 2020
BUY
$31.65 - $46.87 $55,640 - $82,397
1,758 Added 1.09%
162,535 $6.87 Million
Q4 2019

Feb 05, 2020
BUY
$36.21 - $51.4 $496,402 - $704,642
13,709 Added 9.32%
160,777 $6.88 Million
Q3 2019

Oct 23, 2019
SELL
$22.22 - $44.01 $76,925 - $152,362
-3,462 Reduced 2.3%
147,068 $5.29 Million
Q2 2019

Aug 14, 2019
BUY
$23.32 - $28.12 $10,773 - $12,991
462 Added 0.31%
150,530 $4.02 Million
Q1 2019

May 01, 2019
BUY
$16.17 - $27.38 $278,964 - $472,359
17,252 Added 12.99%
150,068 $4.03 Million
Q4 2018

Jan 31, 2019
BUY
$14.32 - $22.92 $637,426 - $1.02 Million
44,513 Added 50.41%
132,816 $2.15 Million
Q3 2018

Nov 07, 2018
SELL
$13.03 - $21.81 $78,375 - $131,187
-6,015 Reduced 6.38%
88,303 $1.83 Million
Q2 2018

Aug 06, 2018
SELL
$15.07 - $22.34 $119,203 - $176,709
-7,910 Reduced 7.74%
94,318 $1.44 Million
Q1 2018

May 02, 2018
SELL
$22.47 - $32.33 $137,786 - $198,247
-6,132 Reduced 5.66%
102,228 $2.3 Million
Q4 2017

Feb 09, 2018
SELL
$26.84 - $39.14 $73,380 - $107,008
-2,734 Reduced 2.46%
108,360 $3.26 Million
Q3 2017

Nov 06, 2017
BUY
$29.49 - $38.37 $3.28 Million - $4.26 Million
111,094
111,094 $4.19 Million

Others Institutions Holding ACAD

# of Institutions
279
Shares Held
156M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email